Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia

EMBO Journal

Volumn 15, Issue 3, 1996, Pages 520-527

  Webster, Melanie K ^a   Donoghue, Daniel J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Achondroplasia; FGFR3; Neu; Receptor activation; Transmembrane domain

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR; PHOSPHOTYROSINE;

ACHONDROPLASIA; AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DWARFISM; HYDROGEN BOND; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0030064347     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1460-2075.1996.tb00384.x     Document Type: Article

References (49)

1. Andersen, P.E., Jr and Hauge, M. (1989) Congenital generalised bone dysplasias: a clinical, radiological, and epidemiological survey. J. Med. Genet., 26, 37-44.
2. Bargmann, C.I. and Weinberg, R.A. (1988a) Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene. Proc. Natl Acad. Sci. USA, 85, 5394-5398.
3. Bargmann, C.I. and Weinberg, R.A. (1988b) Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. EMBO J., 7, 2043-2052.
4. Bargmann, C.I., Hung, M.C. and Weinberg, R.A. (1986) Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell, 45, 649-657.
5. Bellus, G.A., Hefferon, T.W., Ortiz de Luna, R.I., Hecht, J.T., Horton, W.A., Machado, M., Kaitila, I., McIntosh, I. and Francomano, C.A. (1995) Achondroplasia is defined by recurrent G380R mutations of FGFR3. Am. J. Hum. Genet., 56, 368-373.
6. neu* activation. EMBO J., 11, 923-932.
7. Cheatham, B., Shoelson, S.E., Yamada, K., Goncalves, E. and Kahn, C.R. (1993) Substitution of the erbB-2 oncoprotein transmembrane domain activates the insulin receptor and modulates the action of insulin and insulin-receptor substrate 1. Proc. Natl Acad. Sci. USA, 90, 7336-7340.
8. Chellaiah, A.T., McEwen, D.G., Werner, S., Xu, J. and Ornitz, D.M. (1994) Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1. J. Biol. Chem., 269, 11620-11627.
9. Chen, C. and Okayama, H. (1987) High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol., 7, 2745-2752.
10. Drebin, J.A., Link, V.C., Stern, D.F., Weinberg, R.A. and Greene, M.I. (1985) Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell, 41, 697-706.
11. Fantl, W.J., Johnson, D.E. and Williams, L.T. (1993) Signalling by receptor tyrosine kinases. Annu. Rev. Biochem., 62, 453-481.
12. Francomano, C.A. et al. (1994) Localization of the achondroplasia gene to the distal 2.5 Mb of human chromosome 4p. Hum. Mol. Genet., 3, 787-792.
13. Gandelman, K.Y., Gibson, L., Meyn, M.S. and Yang-Feng, T.L. (1992) Molecular definition of the smallest region of deletion overlap in the Wolf-Hirschhorn syndrome. Am. J. Hum. Genet., 51, 571-578.
14. Gullick, W.J., Bottomley, A.C., Lofts, F.J., Doak, D.G., Mulvey, D., Newman, R., Crumpton, M.J., Sternberg, M.J. and Campbell, I.D. (1992) Three dimensional structure of the transmembrane region of the protooncogenic oncogenic forms of the neu protein. EMBO J., 11, 43-48.
15. Iannotti, J.P., Goldstein, S., Kuhn, J., Lipiello, L. and Kaplan, F.S. (1994) Growth plate and bone development. In Simon, S.R. (ed.), Orthopaedic Basic Science. American Academy of Orthopaedic Surgeons, Rosemont, IL, pp. 185-217.
16. Iwamoto, M., Shimazu, A., Nakashima, K., Suzuki, F. and Kato, Y. (1991) Reduction of basic fibroblast growth factor receptor is coupled with terminal differentiation of chondrocytes. J. Biol. Chem., 266, 461-467.
17. Jabs, E.W. et al. (1994) Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2. Nature Genet., 8, 275-279.
18. Johnson, D.E. and Williams, L.T. (1993) Structural and functional diversity in the FGF receptor multigene family. Adv. Cancer Res., 60, 1-41.
19. Kato, Y. and Iwamoto, M. (1990) Fibroblast growth factor is an inhibitor of chondrocyte terminal differentiation. J. Biol. Chem., 265, 5903-5909.
20. Keegan, K., Johnson, D.E., Williams, L.T. and Hayman, M.J. (1991a) Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3. Proc. Natl Acad. Sci. USA, 88, 1095-1099.
21. Keegan, K., Meyer, S. and Hayman, M.J. (1991b) Structural and biosynthetic characterization of the fibroblast growth factor receptor 3 (FGFR-3) protein. Oncogene, 6, 2229-2236.
22. Lee, B.A. and Donoghue, D.J. (1992) Intracellular retention of membrane-anchored v-sis protein abrogates autocrine signal transduction. J. Cell Biol., 118, 1057-1070.
23. Lofts, F.J., Hurst, H.C., Sternberg, M.J. and Gullick, W.J. (1993) Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo. Oncogene, 8, 2813-2820.
24. Maynard, J.A., Ippolito, E.G., Ponseti, I.V. and Mickelson, M.R. (1981) Histochemistry and ultrastructure of the growth plate in achondroplasia. J. Bone Joint Surg., 63, 969-979.
25. Meyer, A.N., Xu, Y.-F., Webster, M.K., Smith, A.E. and Donoghue, D.J. (1994) Cellular transformation by a transmembrane peptide: Structural requirements for the bovine papillomavirus E5 oncoprotein. Proc. Natl Acad. Sci. USA, 91, 4634-4638.
26. Miloso, M., Mazzotti, M., Vass, W.C. and Beguinot, L. (1995) SHC and GRB-2 are constitutively activated by an epidermal growth factor receptor with a point mutation in the transmembrane domain. J. Biol. Chem., 270, 19557-19562.
27. Oberklaid, F., Danks, D.M., Jensen, F., Stace, L. and Rosshandler, S. (1979) Achondroplasia and hypochondroplasia. Comments on frequency, mutation rate, and radiological features in skull and spine. J. Med. Genet., 16, 140-146.
28. Peters, K., Ornitz, D., Wetner, S. and Williams, L. (1993) Unique expression pattern of the FGF receptor 3 gene during mouse organogenesis. Dev. Biol., 155, 423-430.
29. Ponseti, I.V. (1970) Skeletal growth in achondroplasia. J. Bone Joint Surg., 52A, 701-716.
30. Reardon, W., Winter, R.M., Rutland, P., Pulleyn, L.J., Jones, B.M. and Malcolm, S. (1994) Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. Nature Genet., 8, 98-103.
31. Rousseau, F., Bonaventure, J., Legeai-Mallet, L., Pelet, A., Rozet, J., Maroteaux, M.P., Le Merrer, M. and Munnich, A. (1994) Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature, 371, 252-254.
32. Rutland, P. et al. (1995) Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome phenotypes. Nature Genet., 9, 173-176.
33. Scott, G.K., Dodson, J.M., Montgomery, P.A., Johnson, R.M., Sarup, J.C., Wong, W.L., Ullrich, A., Shepard, H.M. and Benz, C.C. (1991) p185HER2 signal transduction in breast cancer cells. J. Biol. Chem., 266, 14300-14305.
34. Segatto, O., King, R., Pierce, J.H., DiFiore, P.P. and Aaronson, S.A. (1988) Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol. Cell. Biol., 8, 5570-5574.
35. Shiang, R., Thompson, L.M., Zhu, Y.Z., Church, D.M., Fielder, T.J., Bocian, M., Winokur, S.T. and Wasmuth, J.J. (1994) Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell, 78, 335-342.
36. Shih, C., Padhy, L.C., Murray, M. and Weinberg, R.A. (1981) Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature, 290, 261-264.
37. Spivak-Kroizman, T. et al. (1994) Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell, 79, 1015-1024.
38. Stern, D.F., Heffernan, P.A. and Weinberg, R.A. (1986) p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. Mol. Cell. Biol., 6, 1729-1740.
39. Stern, D.F., Kamps, M.P. and Cao, H. (1988) Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo. Mol. Cell. Biol., 8, 3969-3973.
40. Sternberg, M.J. and Gullick, W.J. (1989) Neu receptor dimerization. Nature, 339, 587.
41. Sternberg, M.J. and Gullick, W.J. (1990) A sequence motif in the transmembrane region of growth factor receptors with tyrosine kinase activity mediates dimerization. Protein Engng, 3, 245-248.
42. Stoll, C., Dott, B., Roth, M.P. and Alembik, Y. (1989) Birth prevalence rates of skeletal dysplasias. Clin. Genet., 35, 88-92.
43. Tavormina, P.L. et al. (1995) Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nature Genet., 9, 321-328.
44. Ullrich, A. and Schlessinger, J. (1990) Signal transduction by receptors with tyrosine kinase activity. Cell, 61, 203-212.
45. Weiner, D.B., Liu, J., Cohen, J.A., Williams, W.V. and Greene, M.I. (1989) A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature, 339, 230-231.
46. Wides, R.J., Zak, N.B. and Shilo, B.-Z. (1990) Enhancement of tyrosine kinase activity of the Drosophila epidermal growth factor receptor homolog by alterations of the transmembrane domain. Eur. J. Biochem., 189, 637-645.
47. Wilkie, A.O. et al. (1995) Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome. Nature Genet., 9, 165-172.
48. Xu, Y.F., Meyer, A.N., Webster, M.K., Lee, B.A. and Donoghue, D.J. (1993) The v-sis protein retains biological activity as a type II membrane protein when anchored by various signal-anchor domains, including the hydrophobic domain of the bovine papilloma virus E5 oncoprotein. J. Cell Biol., 123, 549-560.
49. Yamada, K., Goncalves, E., Kahn, C.R. and Shoelson, S.E. (1992) Substitution of the insulin receptor transmembrane domain with the c-neu/erbB2 transmembrane domain constitutively activates the insulin receptor kinase in vitro. J. Biol. Chem., 267, 12452-12461.